According to the PAM50 classification, five distinct molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched, basal-like and normal-like) [3] were established and correlate with prognosis and can guide treatment decisions and the enrollment of patients in clinical trials. The gene discussed is ERBB2; the disease is breast carcinoma.